Unicycive Therapeutics reports Q3 2022 net loss of $5.6M and provides pipeline updates

Unicycive Therapeutics, Inc.

2022-Q3 EPS reported -$0.85 revenue$951,000

Completed enrollment of pivotal bioequivalence study for RENAZORB; topline data expected by year-end.
Entered partnership with Lee's Pharmaceutical for RENAZORB in China, receiving $1.0M upfront fee.
Expects clearance for Phase 1 study of UNI-494 in UK by year-end.
Net loss for Q3 2022 was $5.6M vs $5.2M in Q3 2021; cash and equivalents totaled $7.0M.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Unicycive Therapeutics, Inc. reported financial results for three months ended September 30, 2022.

Period: three months ended September 30, 2022
Result: reported results

Exact text from the filing

On November 14, 2022, Unicycive Therapeutics, Inc. issued a press release announcing company highlights and financial results for the three months ended September 30, 2022.

View on SEC.gov

168 earnings releases filed in the last 30 days. Browse all earnings releases →

Unicycive Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001213900-22-071746

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.